Hangzhou Minsheng Binjiang Pharmaceutical Co.,Ltd
A single plant registered with the FDA to make drugs for the US market. Below is where it is and the drugs whose FDA labels list this site as performing a manufacturing step — so if this plant has a problem, these are the products that could be affected.
- Country
- China
- Registered address
- 658 Bin'an Road Binjiang District, Hangzhou, Zhejiang 310051, China (CHN)
- Operations here
- analysislabelmanufacturepack
- FDA identifiers
- FEI 3007498452 · DUNS 547688780
Recent inspection flagged official action
FDA classified an inspection here as OAI (official action indicated) within the last two years — the strongest public warning signal a facility gets. This plant is listed on labels for 6 drugs. A supply problem here can ripple to all of them.
FDA inspection history
Outcomes of closed FDA inspections at this site (drug and biologic program areas).
- OAIDrug Quality Assurance2025-03-07
- NAIDrug Quality Assurance2018-05-11
- VAIDrug Quality Assurance2016-07-29
- VAIDrug Quality Assurance2014-04-25
- VAIDrug Quality Assurance2011-06-10
Drugs this plant is listed as making
6 distinct drugs across 12 products name this site in their FDA label.
- Alendronate SodiumHangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
- Bupropion HydrochlorideMullan Pharmaceutical Inc.
- Bupropion Hydrochloride (Xl)Chartwell RX, LLC
- Montelukast SodiumWestminster Pharmaceuticals, LLC
- Risedronate SodiumHangzhou Minsheng Binjiang Pharmaceutical CO., Ltd
Sources:the establishment's name, address, and country from FDA's Drug Establishments Current Registration Site (DECRS); the drug-to-facility links from DailyMed SPL drug labels, matched by the facility's DUNS number; inspection outcomes from the FDA Data Dashboard, matched by FEI; shortage status from FDA's drug shortage database. More on how this is built. Educational only.